Berberine for SIBO: the 2024-2025 evidence update

← Back to articles

Berberine has become a fixture of integrative protocols for small intestinal bacterial overgrowth (SIBO), often positioned alongside or as an alternative to rifaximin. The honest position, as of 2026, is that the direct evidence is still thin: there is one prospective comparative study of herbal antimicrobials (not berberine alone), a registered head-to-head trial protocol whose results have not yet been published, and a 2025 network meta-analysis that ranked berberine favourably but on a small and heterogeneous evidence base. That is a meaningful step up from "purely theoretical," but it is a long way from the confident claims found in much of the marketing.

What SIBO actually is

SIBO is defined as excessive bacterial colonization of the small intestine, identified historically by jejunal aspirate culture (often using a threshold around 10³–10⁵ CFU/mL, which itself is debated) and more commonly today by glucose or lactulose hydrogen breath testing. The clinical syndrome overlaps heavily with irritable bowel syndrome: bloating, postprandial distention, altered bowel habit, and sometimes malabsorption. Rifaximin, a poorly-absorbed antibiotic, is the most-studied pharmacologic option. A 2021 systematic review and meta-analysis of 26 studies (874 patients) found a pooled breath-test normalization rate of about 59% on intention-to-treat analysis, with a dose-dependent effect — but the five randomized trials within it showed no statistically significant advantage over comparators, underscoring how soft even the antibiotic evidence is. Recurrence after eradication is common, which is part of what drives interest in alternatives.

The one comparative study: Chedid 2014

The most-cited evidence for herbal antimicrobials in SIBO is a prospective study from a Johns Hopkins-affiliated gastroenterology practice. Among 104 patients with a positive lactulose breath test who completed follow-up testing, those given a four-week course of commercial herbal preparations (multi-botanical formulas, several of which contain berberine alongside other compounds) had a negative repeat breath test in 46% of cases (17 of 37), versus 34% (23 of 67) for rifaximin 1,200 mg/day. The difference was not statistically significant (P = 0.24; adjusted odds ratio 1.85, 95% CI 0.77–4.41). Two points are routinely lost in the retelling: this was not a study of berberine as a single agent, and it did not demonstrate superiority — only that herbals were not clearly worse than rifaximin in an open-label, non-placebo-controlled setting.

What the 2024–2025 literature has actually added

Two genuinely new items anchor the "update" in this article's title. First, in 2023 a Chinese group registered and published the protocol for the BRIEF-SIBO trial — an investigator-initiated, open-label randomized study planning to enrol 180 patients to berberine 400 mg twice daily versus rifaximin 400 mg twice daily for two weeks, with breath-test normalization as the primary endpoint and an explicit non-inferiority hypothesis. As of this writing the protocol is published but the results are not, so it cannot yet be cited as evidence of effect. Second, a 2025 Bayesian network meta-analysis of 30 randomized trials (1,552 participants, 12 interventions) reported that berberine carried the highest surface-under-the-cumulative-ranking-curve (SUCRA) value for SIBO eradication in uncomplicated patients. That is the strongest signal to date — but a network ranking built largely on small, partly high-risk-of-bias trials generates hypotheses; it does not establish that berberine beats rifaximin. The authors said exactly that, calling for direct, well-controlled comparisons. We could not find any published randomized trial of berberine monotherapy versus placebo for breath-test-confirmed SIBO.

A separate, sturdier fibre signal

One adjacent finding is more solid than the berberine data and is often conflated with it. A 2010 randomized trial in 77 SIBO patients found that adding partially hydrolysed guar gum (5 g/day) to rifaximin raised glucose-breath-test eradication from 62% with rifaximin alone to 87% (per-protocol; 85% on intention-to-treat). The proposed mechanism is improved small-bowel clearance through the fibre's effect on motility, not any direct antimicrobial action. It is a different intervention from berberine, but it illustrates that the better-supported "natural" adjuncts in SIBO act on gut transit rather than killing bacteria outright.

Mechanism: why berberine is plausible

Berberine is a quaternary isoquinoline alkaloid found in Berberis species and Coptis chinensis. In laboratory work it has direct antimicrobial activity against a range of Gram-negative and Gram-positive organisms and it measurably reshapes gut-microbiota composition. Crucially, oral berberine has very low systemic bioavailability — typically cited as under 5% — so the bulk of an oral dose stays in the gut lumen. That is mechanistically convenient for an intraluminal problem like SIBO, but low bioavailability and substantial between-study heterogeneity are exactly the limitations reviewers flag when explaining why berberine's clinical results are inconsistent. Plausible mechanism is not the same as demonstrated clinical benefit.

Safety and interactions

Berberine is generally tolerated at roughly 0.9–1.5 g/day in divided doses; the most common adverse effects are gastrointestinal (nausea, cramping, constipation, diarrhoea). The interaction profile is the more important caution. Berberine and berberine-containing herbs (goldenseal, Coptis) inhibit or modulate CYP3A and the P-glycoprotein transporter: an in-vivo rat study using cyclosporine as a probe showed berberine-containing Coptidis rhizoma markedly raised cyclosporine exposure, and physiologically-based pharmacokinetic modelling predicts that high-dose berberine can meaningfully increase blood levels of sensitive CYP3A substrates. That matters for anyone taking immunosuppressants (cyclosporine, tacrolimus, sirolimus), certain statins, or other narrow-therapeutic-index cardiovascular drugs. Berberine is also widely advised against in pregnancy and breastfeeding because of long-standing concern that it can displace bilirubin and worsen neonatal jaundice.

Comparing options honestly

Rifaximin remains the option with regulatory approval, the largest (if still imperfect) randomized evidence base, and a well-characterized safety profile. Berberine is supported by mechanism, one non-significant comparative study of multi-herb formulas, a favourable but hypothesis-generating 2025 network ranking, and a head-to-head trial we are still waiting to read out. For a patient who has failed or cannot tolerate rifaximin, a time-limited, clinician-supervised trial of berberine is a defensible choice — but it should be framed as a reasonable experiment, not as an evidence-equivalent substitute. Anyone on the interacting drug classes above, and anyone pregnant or nursing, should not use it.

Sources

1. Chedid V, Dhalla S, Clarke JO, et al. "Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth." Global Advances in Health and Medicine, 2014;3(3):16-24. PMID 24891990.
2. Guo H, Lu S, Zhang J, et al. "Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study)." Frontiers in Pharmacology, 2023;14:1121435. PMID 36873985.
3. Zhang Q, Li H, Chen C, et al. "Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis." Therapeutic Advances in Gastroenterology, 2025;18:17562848251399033. PMID 41394885.
4. Wang J, Zhang L, Hou X. "Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis." Expert Review of Gastroenterology & Hepatology, 2021;15(12):1385-1399. PMID 34767484.
5. Furnari M, Parodi A, Gemignani L, et al. "Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth." Alimentary Pharmacology & Therapeutics, 2010;32(8):1000-1006. PMID 20937045.
6. Asghari P, Babaei A, Zamanian N, Nattagh-Eshtivani E. "Berberine's impact on health: Comprehensive biological, pharmacological, and nutritional perspectives." Metabolism Open, 2025;28:100399. PMID 41089338.
7. Yu CP, Huang CY, Lin SP, Hou YC. "Activation of P-glycoprotein and CYP 3A by Coptidis Rhizoma in vivo: Using cyclosporine as a probe substrate in rats." Journal of Food and Drug Analysis, 2017;26(2S):S125-S132. PMID 29703381.
8. Adiwidjaja J, Boddy AV, McLachlan AJ. "Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib." European Journal of Clinical Pharmacology, 2022;78(4):597-611. PMID 35048143.